tbuckley/cabot-search huggingface dataset:
Review: Automated mobile phone text messaging increases smoking cessation (moderate evidence)
Authors: Allan V. Prochazka
Journal: Annals of Internal Medicine (2020)

ACP Journal Club17 March 2020Review: Automated mobile phone text messaging increases smoking cessation (moderate evidence)Allan V. Prochazka, MD, MScAllan V. Prochazka, MD, MScUniversity of Colorado School of Medicine, Boulder, Colorado, USA (A.V.P.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ202003170-033 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationWhittaker R, McRobbie H, Bullen C, et al. Mobile phone text messaging and app-based interventions for smoking cessation. Cochrane Database Syst Rev. 2019;10:CD006611. https://pubmed.ncbi.nlm.nih.gov/31638271Clinical Impact RatingsGIM/FP/GP: Public Health: References1 Augustson E, Cole-Lewis H, Sanders A, et al. Analysing user-reported data for enhancement of SmokefreeTXT: a national text message smoking cessation intervention. Tob Control. 2017;26:683-9. [PMID: 27852892] Google Scholar2 Akbar S, Coiera E, Magrabi. Safety concerns with consumer-facing mobile health applications and their consequences: a scoping review. J Am Med Inform Assoc. 2020;27:330-40. [PMID: 31599936] Google Scholar3 Siu AL; U.S. Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163:622-34. [PMID: 26389730] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Colorado School of Medicine, Boulder, Colorado, USA (A.V.P.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-3040.This article was published at Annals.org on 3 March 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 March 2020Volume 172, Issue 6Page: JC33KeywordsDatabasesInternetNumber needed to treatPopulation statisticsPrevention, policy, and public healthRisk ratioSmoking cessationTelemedicine ePublished: 17 March 2020 Issue Published: 17 March 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Primary ocular adnexal MALT lymphoma (POAML): A long-term follow up study of 114 patients (pts)
Authors: K. Tanimoto, A. Kaneko, S. Suzuki, N. Sekiguchi, T. Watanabe, Y. Kobayashi, Y. Kagami, A. M. Maeshima, Y. Matsuno, K. Tobinai
Journal: Journal of Clinical Oncology (2006)

7593 Background: Although POAML is a recently recognized distinct entity, its natural history, prognostic factors, behavior of progression and death, and standard initial management have not been fully elucidated. Methods: 114 pts with a histologically verified POAML treated at our institution between 1970 and 2003 were retrospectively analyzed. Results: With a median follow-up duration of 5.7 years (0.6–34.0), estimated overall survival (OS) rate and progression-free survival (PFS) rate at 10 years was 89% and 57%, respectively. Older pts (&gt;60) showed significantly worse OS (p=0.002). However, other clinical factors did not affect significantly OS or PFS. 13 (11%) pts died, but only 3 (3%) due to progressive lymphoma. 31 (27%) pts progressed, 7(6%) at systemic diseases, 8 (7%) at contra lateral sites, and 16 (14%) at the same sites, and only 2 (2%) transformed high-grade lymphoma. All 8 pts who progressed at contra lateral sites were limited to those who had involved initially in the orbit (p=0.036) and their time to progression was significantly longer (p=0.039). Pts who received initially radiation-containing therapy were superior in PFS but not OS than those initially treated with other modalities (p=0.016 and 0.091, respectively). Moreover, when we compared the outcomes of no initial therapy cohort and immediate therapy cohort, there was no significant difference in OS and PFS (p=0.499 and 0.073, respectively). Conclusions: The majority of pts with POAML showed the behaviors of very indolent diseases, and only age was significant prognostic factor. Our preliminary observation suggesting that no initial therapy is an acceptable approach for selected pts (Ann Oncol 2006;17:135–40) was further confirmed in this study for all cohorts. Considering the possible heterogeneity of POAML among initial sites suggested by the present study and the genetic heterogeneity revealed by our previous study (Blood 2005;106:289a), further investigations on POAML are warranted. No significant financial relationships to disclose.
Soothsaying and Prescriptive Analysis as a Treatment Algorithm
Authors: Pamela A. Lipsett
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
EFFECT OF LONGER-TERM ADMINISTRATION OF EVOLOCUMAB IN PATIENTS WITH ANGIOGRAPHIC CORONARY ARTERY DISEASE: RESULTS OF THE GLAGOV OPEN LABELLED EXTENSION STUDY
Authors: Stephen J. Nicholls, Todd Anderson, Christie M. Ballantyne, Leslie Cho, John J.P.P. Kastelein, Wolfgang Koenig, Thomas Hucko, Helina Kassahun, Yimeng Liu, Huei Wang, Steven E. Nissen
Journal: Journal of the American College of Cardiology (2020)
Antagonistic activity of acolbifene, fulvestrant, tamoxifen, and raloxifene on cancer-associated genes in the mouse mammary gland.
Authors: Ezequiel Calvo, Van Luu-The, Céline Martel, Fernand Labrie
Journal: Journal of Clinical Oncology (2012)

10583 Background: The efficacy and exceptionally good tolerance of estrogen blockade in the treatment of breast cancer is well recognized. Acolbifene (ACOL) is a novel and unique SERM completely free of estrogen-like activity in both the mammary gland and uterus. To better understand the specificity of ACOL, we have investigated its effect on the expression of a set of genes modulated by estradiol (E 2 ) in the mouse mammary gland. Methods: ACOL, tamoxifen (TAM), raloxifene (RALOX) and fulvestrant (FULV) were administered (0.01 mg/mouse; sc) to ovariectomized (OVX) mice or to OVX mice simultaneously treated with E 2 (0.05 µg/mouse; single sc injection). Microarray screening followed by Q_RTPCR was used to identify a reproducible set of E 2 responsive genes. Results: From 128 genes significantly modulated by E 2 , 108 genes were up-regulated and 20 were down-regulated. Forty-nine of these genes were associated with tumorigenesis while 22 are known to be associated with breast cancer. This set of 49 genes were used to determine the specificity of ACOL compared to another pure antiestrogen in the mammary gland and uterus, namely FULV, as well as to the mixed estrogen antagonists/agonists TAM and RALOX, in their ability to block the effect of E 2 . Efficacy of reversal of the effect of E 2 was 94%, 63%, 45% and 90% for ACOL, FULV, TAM and RALOX, respectively. The overlap between all treatments was 30.6% (15/49). ACOL reversed the effect of E 2 on 42 of the 49 (85.7%) cancer-related genes. Between the genes up-regulated by E 2 and reversed by ACOL, seven are considered as prognostic markers in breast cancer, namely Fgfr3, Fos12, Junb, Jdp2, Gdf15, Greb1 and Tgm2. On the other hand, two genes down‑regulated by E 2 , namely Foxa1 and Fgfr2, were restored by ACOL. Conclusions: Taken together, these data offer new information for a better understanding of the previously demonstrated potent tumoricidal action of ACOL in human breast cancer xenografts. The data also suggest, under the tested conditions, superiority of ACOL over TAM and the other compounds to reverse the effect of E 2 on specific gene expression, thus supporting the interest of this new 3 rd generation SERM for the hormonal therapy and prevention of breast cancer.
ADVERSE PLAQUE CHARACTERISTICS RELATE MORE STRONGLY WITH INDEX OF MICROCIRCULATORY RESISTANCE THAN CORONARY FLOW RESERVE
Authors: Masahiro Hada, Masahiro Hoshino, Kai Nogami, Hiroki Ueno, Tomoki Horie, Tohru Miasawa, Yohei Sumino, Masao Yamaguchi, Yoshihisa Kanaji, Tomoyo Sugiyama, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2020)
FACTORS ASSOCIATED WITH LATE BLEEDING AFTER A NOVEL RAPID RADIAL HEMOSTASIS STRATEGY USING HYDROPHOBICALLY-MODIFIED CHITOSAN IN CONJUNCTION WITH PNEUMATIC COMPRESSION
Authors: Rajeev Anchan, Stephanie Besser, Christopher Fernandez, Linda Lee, John E. Blair, Rohan Kalathiya, Jonathan D. Paul, Sandeep Nathan
Journal: Journal of the American College of Cardiology (2020)
Obesity may enhance the adverse effects of NO2 exposure in urban schools on asthma symptoms in children
Authors: Perdita Permaul, Jonathan M. Gaffin, Carter R. Petty, Sachin N. Baxi, Peggy S. Lai, William J. Sheehan, Carlos A. Camargo, Diane R. Gold, Wanda Phipatanakul
Journal: Journal of Allergy and Clinical Immunology (2020)
<i>Vital Signs</i>: Colorectal Cancer Screening Test Use — United States, 2018
Authors: Djenaba A. Joseph, Jessica B. King, Nicole F. Dowling, Cheryll C. Thomas, Lisa C. Richardson
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Colorectal cancer (CRC) is the second leading cause of cancer death in the United States of cancers that affect both men and women. Despite strong evidence that screening for CRC reduces incidence and mortality, CRC screening prevalence is below the national target. This report describes current CRC screening prevalence by age, various demographic factors, and state.Data from the 2018 Behavioral Risk Factor Surveillance System survey were analyzed to estimate the percentages of adults aged 50-75 years who reported CRC screening consistent with the United States Preventive Services Task Force recommendation.In 2018, 68.8% of adults were up to date with CRC screening. The percentage up to date was 79.2% among respondents aged 65-75 years and 63.3% among those aged 50-64 years. CRC screening prevalence was lowest among persons aged 50-54 years (50.0%) and increased with age. Among respondents aged 50-64 years, CRC screening prevalence was lowest among persons without health insurance (32.6%) and highest among those with reported annual household income of ≥$75,000 (70.8%). Among respondents aged 65-75 years, CRC screening prevalence was lowest among those without a regular health care provider (45.6%), and highest among those with reported annual household income ≥$75,000 (87.1%). Among states, CRC screening prevalence was highest in Massachusetts (76.5%) and lowest in Wyoming (57.8%).CRC screening prevalence is lower among adults aged 50-64 years, although most reported having a health care provider and health insurance. Concerted efforts are needed to inform persons aged <50 years about the benefit of screening so that screening can start at age 50 years.
TOLVAPTAN ADMINISTRATION AMONG PATIENTS WITH HEART FAILURE IN JAPANESE NATION WIDE REGISTRY
Authors: Makoto Takei, MIchikazu Nakai, Yoko Sumita, Ayaka Endo, Naoki Hirata, Kenji Suzuki, Tasuku Hasegawa, Susumu Nakagawa, Toshiyuki Takahashi
Journal: Journal of the American College of Cardiology (2020)
Abstract 15758: Diagnostic Accuracy of the Confirm RX Internal Loop Recorder for Atrial Fibrillation Detection
Authors: Carola Gianni, Andrew Vu, Ugur Canpolat, Hüseyin Ayhan, Chen Qiong, Bryan MacDonald, Domenico G Della Rocca, Sanghamitra Mohanty, Chintan Trivedi, Amin Al-Ahmad, Mohamed Bassiouny, J D Burkhardt, G J Gallinghouse, Patrick M Hranitzky, Rodney P Horton, Javier Sanchez, Luigi Di Biase, Andrea Natale
Journal: Circulation (2019)

Introduction: Internal loop recorders (ILRs) are increasingly used in AF management, but little is known about the yield of a specific monitoring device/algorithm to detect and monitor AF. Method: ...
Accent-based nomograms (NGs) to predict time to recurrence (TTR) and overall survival (OS) in stage III colon cancer (CC).
Authors: Lindsay A. Renfro, Axel Grothey, Leonard Saltz, Thierry André, Roberto Labianca, Steven R. Alberts, Charles L. Loprinzi, Greg Yothers, Daniel J. Sargent
Journal: Journal of Clinical Oncology (2013)

3618 Background: Current prognostic tools and staging systems in CC use relatively few patient (pt) characteristics; including additional covariates may improve prediction. Using the large ACCENT database, we constructed clinically based NGs for OS and TTR in stage III CC that better separate pts into risk groups compared to AJCC v7 staging. Methods: 15,936 stage III pts accrued to phase III clinical trials since 1989 were used to construct Cox models for TTR and OS. Variables included age, sex, race, BMI, performance status, tumor grade, tumor stage, ratio of positive lymph nodes to nodes examined, number/location of primary tumors (any multiple versus single left, right, or transverse), and treatment (5FU variations vs. 5FU with oxaliplatin or irinotecan). Missing data (&lt;18%) were imputed, continuous variables modeled with splines, and clinically relevant pairwise interactions included if p &lt; 0.001. Final models were internally validated via bootstrapping for corrected calibration and C-indices for survival data. NG-defined risk tertiles were compared to AJCC v7 stage III for observed 3-year (yr) TTR and 5-yr OS for a subset of 7400 pts with complete data. Results: All variables were statistically and clinically significant for OS; age and race did not predict TTR. No meaningful interactions existed. NGs for OS and TTR were well calibrated and associated with C-indices of 0.66 and 0.65, respectively, vs. 0.58 and 0.59 for AJCC. NG risk tertiles were better separated than AJCC groups, (3-yr TTR, 5-yr OS below), with fewer mid-risk NG pts. Removing treatment from NGs did not affect performance (C=0.66 for OS and 0.65 for TTR). Conclusions: The proposed ACCENT NGs are internally valid and have the potential to aid prognostication, decision-making, and patient/physician communication in pts with stage III CC. [Table: see text]
EARLY EXPRESSION OF CIRCULATING LONG NON-CODING RNA CORRELATES WITH THE RISK OF 1-YEAR MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION
Authors: Perman Pandal, Aaron Shulkin, Eliseo Vazquez, Elizabeth Cortez-Toledo, Diana Ramos, Chenoa R. Vargas, Machelle Wilson, Blythe P. Durbin-Johnson, Monica Britton, Matthew Lee Settles, Javier E. López
Journal: Journal of the American College of Cardiology (2020)
THE APTAMER BC 007 FOR THE TREATMENT OF DILATED CARDIOMYOPATHIES WITH POSITIVITY FOR ANTI-β1-ADRENOCEPTOR AUTOANTIBODIES: DATA FROM STUDIES IN DOBERMAN PINSCHERS AND HUMANS
Authors: Ingolf Schimke, Niels Becker, Gerd Wallukat, Katrin Wenzel, Annekathrin Haberland, Peter Goettel, Sarah Schulze-Rothe, Sabine Werner, Anne-Sophie Hoenicke, Susanne Becker, Gerhard Wess, Johannes Mueller
Journal: Journal of the American College of Cardiology (2020)
Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors
Authors: Joseph Song, Priyanka Kadaba, Amanda Kravitz, Adilia Hormigo, Joshua Friedman, Puneet Belani, Constantinos Hadjipanayis, Benjamin M Ellingson, Kambiz Nael
Journal: Neuro-Oncology (2020)

Abstract Background Physiologic changes quantified by diffusion and perfusion MRI have shown utility in predicting treatment response in glioblastoma (GBM) patients treated with cytotoxic therapies. We aimed to investigate whether quantitative changes in diffusion and perfusion after treatment by immune checkpoint inhibitors (ICIs) would determine 6-month progression-free survival (PFS6) in patients with recurrent GBM. Methods Inclusion criteria for this retrospective study were: (i) diagnosis of recurrent GBM treated with ICIs and (ii) availability of diffusion and perfusion in pre and post ICI MRI (iii) at ≥6 months follow-up from treatment. After co-registration, mean values of the relative apparent diffusion coefficient (rADC), Ktrans (volume transfer constant), Ve (extravascular extracellular space volume) and Vp (plasma volume), and relative cerebral blood volume (rCBV) were calculated from a volume-of-interest of the enhancing tumor. Final assignment of stable/improved versus progressive disease was determined on 6-month follow-up using modified Response Assessment in Neuro-Oncology criteria. Results Out of 19 patients who met inclusion criteria and follow-up (mean ± SD: 7.8 ± 1.4 mo), 12 were determined to have tumor progression, while 7 had treatment response after 6 months of ICI treatment. Only interval change of rADC was suggestive of treatment response. Patients with treatment response (6/7: 86%) had interval increased rADC, while 11/12 (92%) with tumor progression had decreased rADC (P = 0.001). Interval change in rCBV, Ktrans, Vp, and Ve were not indicative of treatment response within 6 months. Conclusions In patients with recurrent GBM, interval change in rADC is promising in assessing treatment response versus progression within the first 6 months following ICI treatment. Key Points • In recurrent GBM treated with ICIs, interval change in rADC suggests early treatment response. • Interval change in rADC can be used as an imaging biomarker to determine PFS6. • Interval change in MR perfusion and permeability measures do not suggest ICI treatment response.
Rammya Mathew: Learning to manage multimorbidity
Authors: Rammya Mathew
Journal: BMJ (2020)

Looking after people with multiple health conditions is challenging, especially in the context of ageing, frailty, and deteriorating health. Although the National Institute for Health and Care Excellence (NICE) guidelines on multimorbidity provide some valuable principles,1 it’s still far from clear how we care for such patients.

As clinicians, we’re grappling with many unknowns in terms of the evidence base, and we have to use our clinical judgment and experience to help patients make decisions that make sense for them. Often this means weighing up the risks and benefits of starting or stopping medicines or deciding whether to initiate …
Analysis of serum HER-2/neu levels (S-HER2) in breast cancer (BC) patients (pts)
Authors: S. Palmeri, A. Mangiameli, M. Vaglica, R. Allegro, M. C. Macaluso, A. Bongiovanni, L. Di Noto, D. Vasta, L. Raciti, D. Lio
Journal: Journal of Clinical Oncology (2006)

20092 Background: Circulating serum levels of the extracellular domain of the HER-2/neu receptor have been described in up to 15–30% of pre-surgical BC pts and 45% of metastatic BC (MBC) pts. S-HER2 has been reported to have a potential prognostic and predictive role in BC pts. Methods: We conducted a prospective evaluation of the S-HER2 levels in BC pts with the aim of studying its prognostic role and correlation with the clinical situation.The S-HER-2 levels were measured by an ELISA immunometric test (cut-off 13 ng/ml) at the first visit and then every 3 months.All pts gave a written informed consent. Results: From Jan ‘05 97 consecutive BC pts [68 st I-III; 29 (1 male) st.IV; median age at entry: 60y (28–83)] have been accrued and a total of 196 serum samples have been tested for S-HER2 (mean = 2/pt).Preliminary results are reported.Elevated S-HER2 levels at the first dosage (bS-HER2) were present in 25% of primary and 52% of MBC pts.In 68 primary BC pts the tumor HER2 status was 0/1+ in 54% (bS-HER2 &gt;13 ng/ml = 22%) and 2+/3+ in 22% (bS-HER2 &gt;13 ng/ml = 27%); there was no correlation between bS-HER2 with tumor HER2 status, size,axillary nodes, ER status, grading according to the Fisher’s exact test. In 29 MBC pts the tumor HER2 status was 0/1+ in 24% (bS-HER2 &gt;13 ng/ml = 24%) and 2+/3+ in 48% (bS-HER2 &gt;13 ng/ml = 21%); there was no correlation between S-HER2 and sites of metastases/n.of sites even if the S-HER2 median value was 18 and 12.5 ng/ml in visceral vs no visceral metastases.We also observed in 35% of MBC pts experiencing progression of disease that S-HER2 sequential values increased from baseline;in 21% of MBC pts that experienced complete remission the S-HER2 values decreased &lt;13 from baseline. Conclusions: This analysis showed no definite association between bS-HER-2 and clinical parameters.Further evaluations in a larger group of pts and association with response,survival and changes of S-HER2 status will be conducted. No significant financial relationships to disclose.
Sleep disturbances and predictors of nondeployability among active-duty Army soldiers: an odds ratio analysis of medical healthcare data from fiscal year 2018
Authors: Jaime K. Devine, Jacob Collen, Jake J. Choynowski, Vincent Capaldi
Journal: Military Medical Research (2020)

The impact of sleep disorders on active-duty soldiers' medical readiness is not currently quantified. Patient data generated at military treatment facilities can be accessed to create research reports and thus can be used to estimate the prevalence of sleep disturbances and the role of sleep on overall health in service members. The current study aimed to quantify sleep-related health issues and their impact on health and nondeployability through the analysis of U.S. military healthcare records from fiscal year 2018 (FY2018).Medical diagnosis information and deployability profiles (e-Profiles) were queried for all active-duty U.S. Army patients with a concurrent sleep disorder diagnosis receiving medical care within FY2018. Nondeployability was predicted from medical reasons for having an e-Profile (categorized as sleep, behavioral health, musculoskeletal, cardiometabolic, injury, or accident) using binomial logistic regression. Sleep e-Profiles were investigated as a moderator between other e-Profile categories and nondeployability.Out of 582,031 soldiers, 48.4% (n = 281,738) had a sleep-related diagnosis in their healthcare records, 9.7% (n = 56,247) of soldiers had e-Profiles, and 1.9% (n = 10,885) had a sleep e-Profile. Soldiers with sleep e-Profiles were more likely to have had a motor vehicle accident (pOR (prevalence odds ratio) =4.7, 95% CI 2.63-8.39, P ≤ 0.001) or work/duty-related injury (pOR = 1.6, 95% CI 1.32-1.94, P ≤ 0.001). The likelihood of nondeployability was greater in soldiers with a sleep e-Profile and a musculoskeletal e-Profile (pOR = 4.25, 95% CI 3.75-4.81, P ≤ 0.001) or work/duty-related injury (pOR = 2.62, 95% CI 1.63-4.21, P ≤ 0.001).Nearly half of soldiers had a sleep disorder or sleep-related medical diagnosis in 2018, but their sleep problems are largely not profiled as limitations to medical readiness. Musculoskeletal issues and physical injury predict nondeployability, and nondeployability is more likely to occur in soldiers who have sleep e-Profiles in addition to these issues. Addressing sleep problems may prevent accidents and injuries that could render a soldier nondeployable.